Peer Review reports
From: Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
| Original Submission | ||
|---|---|---|
| 1 Jan 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 18 Mar 2022 | Reviewed | Reviewer Report - Carlo Piccinni |
| 26 Apr 2022 | Reviewed | Reviewer Report |
| 27 May 2022 | Author responded | Author comments - Jianxiong Deng |
| Resubmission - Version 3 | ||
| 27 May 2022 | Submitted | Manuscript version 3 |
| 30 May 2022 | Author responded | Author comments - Jianxiong Deng |
| Resubmission - Version 4 | ||
| 30 May 2022 | Submitted | Manuscript version 4 |
| 7 Jun 2022 | Author responded | Author comments - Jianxiong Deng |
| Resubmission - Version 5 | ||
| 7 Jun 2022 | Submitted | Manuscript version 5 |
| 9 Jun 2022 | Author responded | Author comments - Jianxiong Deng |
| Resubmission - Version 6 | ||
| 9 Jun 2022 | Submitted | Manuscript version 6 |
| 24 Jun 2022 | Reviewed | Reviewer Report |
| 27 Jun 2022 | Reviewed | Reviewer Report - Carlo Piccinni |
| Resubmission - Version 7 | ||
| Submitted | Manuscript version 7 | |
| Publishing | ||
| 28 Jun 2022 | Editorially accepted | |
| 16 Jul 2022 | Article published | 10.1186/s40360-022-00585-3 |
You can find further information about peer review here.